Table 1 Characteristics of and treatments received by patients

ID	Age (year)	Sex	HLA typing	PS	No. of disease sites	Site of disease	Total no. of CT lines	Previous RT status	Disease status at accrual	Best overall response	Time to tumor response (days)	Duration of response (days)	Time to tumor progression (days)	Survival time (days)
1^a	37	M	6/6	1	4	PNS, bone, lung, LN	3	Y	PD	NE			186	186^b
2^a	49	M	6/6	2	3	Liver, bone, LN	1	Y	PD	PD			84	117^b
3^a	54	M	6/6	1	2	Liver, LN	1	N	SD	PD			94	754^b
4^a	34	F	6/6	1	2	Lungs, LN	2	Y	SD	PR	41	119	160	194^b
5^a	38	M	6/6	0	4	Pleural, lung, spleen, bone	5	Y	PR	NE			91	91^c
6^a	57	M	6/6	1	3	LN, lung, liver	1	Y	PD	SD			110	513^b
7^a	44	F	6/6	0	3	LN, lung, bone	1	Y	PD	PR	662	211	118	1014^b
8^a	51	M	5/6	1	4	Liver, lung, bone, LN	1	Y	SD	NE			54^d	226^b
9^a	45	F	6/6	1	4	PNS, cx-LN, retroph-LN, bone	3	Y	PD	SD			344	426^b
10^a	43	M	6/6	1	3	Lung, bone, liver	3	Y	PD	PD			57	236^b
11^e	49	F	6/6	2	4	Lung, bone, liver, pleural	3	Y	PD	PD			72	107^b
12^e	40	M	6/6	0	3	Liver, LN, PNS	3	Y	PD	PD			57	211^b
13^e	51	M	6/6	1	3	PNS, liver, lung	2	Y	PD	PR	36	64	100	209^b
14^e	46	M	6/6	2	4	LN, pleural, bone, dermis	8	Y	PD	PR	57	71	128	128^f
15^e	48	F	6/6	1	4	Liver, LN, lung, bone	2	Y	PD	PD			58	114^b
16^e	49	M	6/6	1	4	Lung, BM, bone, LN	1	Y	PD	PR	129	396	525	774^b
17^e	55	M	6/6	1	5	Liver, bone, LN, lung, spleen	2	Y	PD	PD			66	210^b
18^e	45	M	6/6	1	2	Lung, LN	2	Y	PD	PR	26	77	103	1147^g
19^e	49	M	5/6	1	4	PNS, LN, bone, liver	3	Y	PD	PR	101	36	137	137^f
20^e	48	F	6/6	2	4	SVCO, lung, liver, LN	5	Y	PD	SD			142^d	143^b
21^e	44	M	6/6	1	3	LN, liver, bone	3	Y	PD	NE			4	4^h

Abbreviations: CT=chemotherapy; cx=cervical; F=female; LN=lymph nodes; M=male; N=no; NE=not evaluable; PD=progressive disease; PNS=posterior nasal space; PR=partial response; PS=performance status according to Eastern Cooperative Oncology Group criteria; retroph=retropharyngeal; RT=radiotherapy; SD=stable disease; SVCO=superior vena cava obstruction; Y=yes.
Note: Time to tumor response, time to tumor progression and survival time were calculated from the date of transplantation.
^aTreated with regimen 1: thymoglobulin at 2.5 mg/kg/day on day −1, +1, +3 and +5.
^bDied due to progressive disease.
^cDied due to acute GVHD.
^dDisease progression detected during clinical examination.
^eTreated with regimen 2: thymoglobulin at 2.5 mg/kg/day on day −1, +1, +2 and +3.
^fDied due to infection.
^gAlive.
^hDied due to pulmonary embolism.

Search